Kidney outcomes and safety of sodium-glucose cotransporter-2 inhibitor therapy in autosomal dominant polycystic kidney disease: systematic review and meta-analysis.

Plain language

Diabetes drugs that protect kidneys (SGLT2 inhibitors) were never properly tested in ADPKD — those patients were left out of the big trials. Pooling six small studies (451 patients), kidney decline slowed a little in year one, with no clear effect on kidney size. Promising but thin evidence.